VAL-083 Phase 3 Study in Temozolomide-Avastin (Bevacizumab) Recurrent GBM
Public ClinicalTrials.gov record NCT03149575. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Pivotal Randomized, Controlled Trial of VAL-083 in Patients With Recurrent Glioblastoma Who Have Failed Standard Temozolomide/Radiation Therapy and Bevacizumab (STAR-3)
Study identification
- NCT ID
- NCT03149575
- Recruitment status
- Terminated
- Study type
- Interventional
- Phase
- Phase 3
- Lead sponsor
- DelMar Pharmaceuticals, Inc.
- Industry
- Enrollment
- 2 participants
Conditions and interventions
Conditions
Interventions
- VAL-083, Dianhydrogalactitol Drug
- Physician's Choice of Salvage Therapy - temozolomide Drug
- Physician's Choice of Salvage Therapy - lomustine Drug
- Physician's Choice of Salvage Therapy - carboplatin Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Oct 26, 2017
- Primary completion
- May 30, 2019
- Completion
- Aug 30, 2019
- Last update posted
- Sep 3, 2025
2017 – 2019
United States locations
- U.S. sites
- 5
- U.S. states
- 4
- U.S. cities
- 5
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Kaiser Permanente Los Angeles Medical Center | Los Angeles | California | 90027 | — |
| University of California, San Francisco - Division of Neuro-Oncology | San Francisco | California | 94143 | — |
| Mayo Clinic Cancer Center | Rochester | Minnesota | 55905 | — |
| Atlantic Neuroscience Institute - Brain Tumor Center of NJ | Summit | New Jersey | 07901 | — |
| Dent Neurosciences Research Center | Amherst | New York | 14226 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT03149575, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Sep 3, 2025 · Synced Jul 24, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT03149575 live on ClinicalTrials.gov.